Pembrolizumab vs Upadacitinib
Pembrolizumab vs Upadacitinib: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Upadacitinib.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days; Upadacitinib — 9-14 hours.
Chemical Properties
Molecular Formula: Upadacitinib — C17H19F3N6O.
Molecular Weight: Upadacitinib — 380.3700 g/mol.
Type: Pembrolizumab — Antibody; Upadacitinib — Small molecule.